Opaleye Management
BOSTON, MAfiles as Opaleye Management Inc.
$1.1bn in 58 US stocks at the end of 30 June 2026. The top 10 are 64.8% of the money. It changed about 22.6% of the portfolio this quarter.
Value
$1.1bn
Stocks
58
Top 10 share
64.8%
Turnover
22.6%
What changed this quarter
New
Bought for the first time this quarter.
- Immix BiopharmaIMMX2.2% of the fund
- Monte Rosa TherapeuticsGLUE1.6% of the fund
- Replimune GroupREPL1.4% of the fund
- VerastemVSTM0.6% of the fund
- Phathom PharmaceuticalsPHAT0.2% of the fund
- Inhibrx BiosciencesINBX0.2% of the fund
- Hemab Therapeutics HoldingsCOAG0.2% of the fund
- First Tracks BiotherapeuticsTRAX0.1% of the fund
- BiohavenBHVN0.1% of the fund
- Pasithea TherapeuticsKTTA<0.1% of the fund
- ADC Therapeutics SAADCT<0.1% of the fund
- OKYO PharmaOKYO<0.1% of the fund
- Palatin TechnologiesPTN<0.1% of the fund
Added
Bought more of a stock they already held.
- Disc MedicineIRON5.7% of the fund+103%
- MeiraGTx HoldingsMGTX4.3% of the fund+67%
- Alpha CognitionACOG1.9% of the fund+13%
- Xoma Royalty1.3% of the fund+13%
- Editas MedicineEDIT1.1% of the fund+100%
- Cabaletta BioCABA1.1% of the fund+180%
- BridgeBio Oncology TherapeuticsBBOT0.5% of the fund+1214%
- Lyell ImmunopharmaLYEL0.4% of the fund+335%
- 4D Molecular TherapeuticsFDMT0.4% of the fund+198%
- Intellia TherapeuticsNTLA0.4% of the fund+2%
- Voyager TherapeuticsVYGR0.4% of the fund+3%
- Rocket PharmaceuticalsRCKT0.3% of the fund+5%
Cut
Sold some of their stake.
- LiquidiaLQDA17.7% of the fund-4%
- HarrowHROW9.2% of the fund-15%
- Q32 BioQTTB1.1% of the fund-26%
- AnnexonANNX0.9% of the fund-26%
- Trevi TherapeuticsTRVI0.5% of the fund-10%
- BiodesixBDSX0.4% of the fund-24%
- Jade BiosciencesJBIO0.3% of the fund-66%
- SANUWAVE HealthSNWV0.3% of the fund-69%
- Fortress BiotechFBIO0.2% of the fund-15%
- Journey MedicalDERM0.2% of the fund-64%
- CG OncologyCGON0.1% of the fund-81%
- Atea PharmaceuticalsAVIR<0.1% of the fund-27%
Sold out
Sold their entire stake.
- Perspective TherapeuticsCATX-100%
- Assertio Holdings-100%
- Sutro BiopharmaSTRO-100%
- Tectonic TherapeuticTECX-100%
- Rigel PharmaceuticalsRIGL-100%
- NextCureNXTC-100%
- Perspective Therapeutics-100%
- Protalix BioTherapeuticsPLX-100%
- LB PharmaceuticalsLBRX-100%
Holdings
- Apogee TherapeuticsAPGE
- Share
- 4.7%
- Value
- $52m
- Shares
- 390,000
Held
- Xoma Royalty
- Share
- 1.3%
- Value
- $14m
- Shares
- 338,374
+13%
- Hemab Therapeutics HoldingsCOAG
- Share
- 0.2%
- Value
- $2m
- Shares
- 47,652
New
- First Tracks BiotherapeuticsTRAX
- Share
- 0.1%
- Value
- $1m
- Shares
- 65,000
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| LiquidiaLQDA | 17.7% | $195m | 2,447,500 | -4% |
| Eton PharmaceuticalsETON | 9.4% | $104m | 2,860,000 | Held |
| HarrowHROW | 9.2% | $102m | 2,400,000 | -15% |
| Disc MedicineIRON | 5.7% | $63m | 855,000 | +103% |
| UroGen PharmaURGN | 4.8% | $53m | 1,439,996 | Held |
| Apogee TherapeuticsAPGE | 4.7% | $52m | 390,000 | Held |
| MeiraGTx HoldingsMGTX | 4.3% | $48m | 3,550,000 | +67% |
| Sol-Gel TechnologiesSLGL | 3.4% | $37m | 500,000 | Held |
| RezoluteRZLT | 3.0% | $33m | 6,300,000 | Held |
| TG TherapeuticsTGTX | 2.7% | $29m | 535,000 | Held |
| Immix BiopharmaIMMX | 2.2% | $24m | 2,345,000 | New |
| Crescent BiopharmaCBIO | 2.2% | $24m | 1,319,351 | Held |
| Stoke TherapeuticsSTOK | 2.1% | $23m | 700,000 | Held |
| Alpha CognitionACOG | 1.9% | $21m | 2,895,467 | +13% |
| Edgewise TherapeuticsEWTX | 1.8% | $20m | 500,000 | Held |
| Revolution MedicinesRVMD | 1.7% | $19m | 100,000 | Held |
| Monte Rosa TherapeuticsGLUE | 1.6% | $18m | 745,000 | New |
| AlumisALMS | 1.4% | $15m | 550,000 | Held |
| CodexisCDXS | 1.4% | $15m | 6,785,000 | Held |
| Replimune GroupREPL | 1.4% | $15m | 1,384,993 | New |
| Xoma Royalty | 1.3% | $14m | 338,374 | +13% |
| MBX BiosciencesMBX | 1.3% | $14m | 260,000 | Held |
| Rhythm PharmaceuticalsRYTM | 1.2% | $14m | 122,500 | Held |
| Editas MedicineEDIT | 1.1% | $13m | 3,861,930 | +100% |
| Protagonist TherapeuticsPTGX | 1.1% | $12m | 100,000 | Held |
| Cabaletta BioCABA | 1.1% | $12m | 3,863,800 | +180% |
| Q32 BioQTTB | 1.1% | $12m | 931,000 | -26% |
| AnnexonANNX | 0.9% | $10m | 1,714,451 | -26% |
| VerastemVSTM | 0.6% | $7m | 1,800,000 | New |
| Zentalis PharmaceuticalsZNTL | 0.6% | $7m | 1,412,656 | Held |
| Relmada TherapeuticsRLMD | 0.6% | $6m | 935,000 | Held |
| Ocular TherapeutixOCUL | 0.5% | $6m | 600,000 | Held |
| Trevi TherapeuticsTRVI | 0.5% | $6m | 310,000 | -10% |
| BridgeBio Oncology TherapeuticsBBOT | 0.5% | $5m | 700,000 | +1214% |
| Lyell ImmunopharmaLYEL | 0.4% | $5m | 344,025 | +335% |
| Opus GeneticsIRD | 0.4% | $5m | 1,125,000 | Held |
| 4D Molecular TherapeuticsFDMT | 0.4% | $4m | 334,437 | +198% |
| Intellia TherapeuticsNTLA | 0.4% | $4m | 250,000 | +2% |
| Voyager TherapeuticsVYGR | 0.4% | $4m | 1,185,000 | +3% |
| BiodesixBDSX | 0.4% | $4m | 180,000 | -24% |
| Rocket PharmaceuticalsRCKT | 0.3% | $3m | 1,000,000 | +5% |
| Jade BiosciencesJBIO | 0.3% | $3m | 145,000 | -66% |
| SANUWAVE HealthSNWV | 0.3% | $3m | 306,140 | -69% |
| Fortress BiotechFBIO | 0.2% | $3m | 890,000 | -15% |
| Journey MedicalDERM | 0.2% | $2m | 350,000 | -64% |
| Phathom PharmaceuticalsPHAT | 0.2% | $2m | 185,589 | New |
| Inhibrx BiosciencesINBX | 0.2% | $2m | 20,291 | New |
| Enanta PharmaceuticalsENTA | 0.2% | $2m | 125,000 | Held |
| Hemab Therapeutics HoldingsCOAG | 0.2% | $2m | 47,652 | New |
| First Tracks BiotherapeuticsTRAX | 0.1% | $1m | 65,000 | New |
| CG OncologyCGON | 0.1% | $1m | 17,789 | -81% |
| BiohavenBHVN | 0.1% | $1m | 77,915 | New |
| Atea PharmaceuticalsAVIR | <0.1% | $1m | 235,000 | -27% |
| Pasithea TherapeuticsKTTA | <0.1% | $1m | 2,050,000 | New |
| ADC Therapeutics SAADCT | <0.1% | $749,000 | 700,000 | New |
| OKYO PharmaOKYO | <0.1% | $562,806 | 375,204 | New |
| Palatin TechnologiesPTN | <0.1% | $221,195 | 20,500 | New |
| Adagio Medical HoldingsADGM | <0.1% | $13,353 | 18,444 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 128.3% since 30 June 2025.
Where the money is
Health care97.3%
Materials1.4%
Other1.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.